Matwings, an AI-based protein design service provider headquartered in Shanghai, has announced the successful completion of its Series A financing round, raising over RMB100 million (USD 13.82 million). The round was led by Qiming Venture Partners, with additional investments from Yonghua Capital, Jingtao Private Equity Fund, and 3E Bioventures, among others. The funds will be allocated towards the development of in-house programs and the iteration and upgrade of Matwings’ independently developed general AI for protein design, AccelProtein.
Company Background and Innovation
Founded in 2021 by an elite team from Shanghai Jiao Tong University, Matwings has been addressing core issues in the protein design industry. The company’s flagship product, AccelProtein, tackles challenges such as long design cycles, high costs, low success rates, and the complexities of multi-objective optimization that have traditionally been managed through “expert experience & extensive trial-and-error” paradigms.
Expanding Applications and Market Reach
Matwings’ offerings have expanded into a variety of fields, including innovative biologics, in vitro diagnostics, pharmaceutical intermediates, nutrition and healthcare, food and beverages, beauty and skincare, textile cleaning, bioenergy, bio-agriculture, and environmental engineering. This diversification reflects the broad applicability of AI-driven protein design and the potential for Matwings to revolutionize these industries.-Fineline Info & Tech
Leave a Reply